 | • レポートコード：QYR2104Z0090 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、134ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品、ヘルスケア |
| Single User | ￥546,000 (USD3,900) | ▷ お問い合わせ |
| Multi User/Five User | ￥819,000 (USD5,850) | ▷ お問い合わせ |
| Enterprise License（同一法人内共有可） | ￥1,092,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査資料では、アジソン病治療薬のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（経口薬、非経口薬）、用途別市場規模（病院、専門クリニック）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・アジソン病治療薬の市場動向 ・企業の競争状況、市場シェア ・アジソン病治療薬の種類別市場規模（経口薬、非経口薬） ・アジソン病治療薬の用途別市場規模（病院、専門クリニック） ・アジソン病治療薬の北米市場規模2016-2027（アメリカ、カナダ） ・アジソン病治療薬のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・アジソン病治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・アジソン病治療薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・アジソン病治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Bristol-Myers Squibb、Merck、Novartis、Pfizer、Takeda Pharmaceutical、Bio-Techne、GlaxoSmithKline、Lupin Pharmaceuticals、Abbott、Amgen、Bayer、Biogen、Eli Lilly and Company、Boehringer Ingelheim International、Diurnal、Switzer Life Science、Recipharm） ・結論 |
Some options for treatment include oral corticosteroids such as: Hydrocortisone (Cortef), prednisone or methylprednisolone to replace cortisol.
Market Analysis and Insights: Global Addison’s Disease Drugs Market
The global Addison’s Disease Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Addison’s Disease Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Addison’s Disease Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Addison’s Disease Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Addison’s Disease Drugs market.
Global Addison’s Disease Drugs Scope and Market Size
Addison’s Disease Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Addison’s Disease Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Oral Drugs
Parenteral Drugs
Segment by Application
Hospitals
Specialty Clinics
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Bristol-Myers Squibb
Merck
Novartis
Pfizer
Takeda Pharmaceutical
Bio-Techne
GlaxoSmithKline
Lupin Pharmaceuticals
Abbott
Amgen
Bayer
Biogen
Eli Lilly and Company
Boehringer Ingelheim International
Diurnal
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Addison’s Disease Drugs Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Oral Drugs
1.2.3 Parenteral Drugs
1.3 Market by Application
1.3.1 Global Addison’s Disease Drugs Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Specialty Clinics
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Addison’s Disease Drugs Market Perspective (2016-2027)
2.2 Addison’s Disease Drugs Growth Trends by Regions
2.2.1 Addison’s Disease Drugs Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Addison’s Disease Drugs Historic Market Share by Regions (2016-2021)
2.2.3 Addison’s Disease Drugs Forecasted Market Size by Regions (2022-2027)
2.3 Addison’s Disease Drugs Industry Dynamic
2.3.1 Addison’s Disease Drugs Market Trends
2.3.2 Addison’s Disease Drugs Market Drivers
2.3.3 Addison’s Disease Drugs Market Challenges
2.3.4 Addison’s Disease Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Addison’s Disease Drugs Players by Revenue
3.1.1 Global Top Addison’s Disease Drugs Players by Revenue (2016-2021)
3.1.2 Global Addison’s Disease Drugs Revenue Market Share by Players (2016-2021)
3.2 Global Addison’s Disease Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Addison’s Disease Drugs Revenue
3.4 Global Addison’s Disease Drugs Market Concentration Ratio
3.4.1 Global Addison’s Disease Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Addison’s Disease Drugs Revenue in 2020
3.5 Addison’s Disease Drugs Key Players Head office and Area Served
3.6 Key Players Addison’s Disease Drugs Product Solution and Service
3.7 Date of Enter into Addison’s Disease Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Addison’s Disease Drugs Breakdown Data by Type
4.1 Global Addison’s Disease Drugs Historic Market Size by Type (2016-2021)
4.2 Global Addison’s Disease Drugs Forecasted Market Size by Type (2022-2027)
5 Addison’s Disease Drugs Breakdown Data by Application
5.1 Global Addison’s Disease Drugs Historic Market Size by Application (2016-2021)
5.2 Global Addison’s Disease Drugs Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Addison’s Disease Drugs Market Size (2016-2027)
6.2 North America Addison’s Disease Drugs Market Size by Type
6.2.1 North America Addison’s Disease Drugs Market Size by Type (2016-2021)
6.2.2 North America Addison’s Disease Drugs Market Size by Type (2022-2027)
6.2.3 North America Addison’s Disease Drugs Market Size by Type (2016-2027)
6.3 North America Addison’s Disease Drugs Market Size by Application
6.3.1 North America Addison’s Disease Drugs Market Size by Application (2016-2021)
6.3.2 North America Addison’s Disease Drugs Market Size by Application (2022-2027)
6.3.3 North America Addison’s Disease Drugs Market Size by Application (2016-2027)
6.4 North America Addison’s Disease Drugs Market Size by Country
6.4.1 North America Addison’s Disease Drugs Market Size by Country (2016-2021)
6.4.2 North America Addison’s Disease Drugs Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe Addison’s Disease Drugs Market Size (2016-2027)
7.2 Europe Addison’s Disease Drugs Market Size by Type
7.2.1 Europe Addison’s Disease Drugs Market Size by Type (2016-2021)
7.2.2 Europe Addison’s Disease Drugs Market Size by Type (2022-2027)
7.2.3 Europe Addison’s Disease Drugs Market Size by Type (2016-2027)
7.3 Europe Addison’s Disease Drugs Market Size by Application
7.3.1 Europe Addison’s Disease Drugs Market Size by Application (2016-2021)
7.3.2 Europe Addison’s Disease Drugs Market Size by Application (2022-2027)
7.3.3 Europe Addison’s Disease Drugs Market Size by Application (2016-2027)
7.4 Europe Addison’s Disease Drugs Market Size by Country
7.4.1 Europe Addison’s Disease Drugs Market Size by Country (2016-2021)
7.4.2 Europe Addison’s Disease Drugs Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Addison’s Disease Drugs Market Size (2016-2027)
8.2 Asia-Pacific Addison’s Disease Drugs Market Size by Type
8.2.1 Asia-Pacific Addison’s Disease Drugs Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Addison’s Disease Drugs Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Addison’s Disease Drugs Market Size by Type (2016-2027)
8.3 Asia-Pacific Addison’s Disease Drugs Market Size by Application
8.3.1 Asia-Pacific Addison’s Disease Drugs Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Addison’s Disease Drugs Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Addison’s Disease Drugs Market Size by Application (2016-2027)
8.4 Asia-Pacific Addison’s Disease Drugs Market Size by Region
8.4.1 Asia-Pacific Addison’s Disease Drugs Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Addison’s Disease Drugs Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Addison’s Disease Drugs Market Size (2016-2027)
9.2 Latin America Addison’s Disease Drugs Market Size by Type
9.2.1 Latin America Addison’s Disease Drugs Market Size by Type (2016-2021)
9.2.2 Latin America Addison’s Disease Drugs Market Size by Type (2022-2027)
9.2.3 Latin America Addison’s Disease Drugs Market Size by Type (2016-2027)
9.3 Latin America Addison’s Disease Drugs Market Size by Application
9.3.1 Latin America Addison’s Disease Drugs Market Size by Application (2016-2021)
9.3.2 Latin America Addison’s Disease Drugs Market Size by Application (2022-2027)
9.3.3 Latin America Addison’s Disease Drugs Market Size by Application (2016-2027)
9.4 Latin America Addison’s Disease Drugs Market Size by Country
9.4.1 Latin America Addison’s Disease Drugs Market Size by Country (2016-2021)
9.4.2 Latin America Addison’s Disease Drugs Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Addison’s Disease Drugs Market Size (2016-2027)
10.2 Middle East & Africa Addison’s Disease Drugs Market Size by Type
10.2.1 Middle East & Africa Addison’s Disease Drugs Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Addison’s Disease Drugs Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Addison’s Disease Drugs Market Size by Type (2016-2027)
10.3 Middle East & Africa Addison’s Disease Drugs Market Size by Application
10.3.1 Middle East & Africa Addison’s Disease Drugs Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Addison’s Disease Drugs Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Addison’s Disease Drugs Market Size by Application (2016-2027)
10.4 Middle East & Africa Addison’s Disease Drugs Market Size by Country
10.4.1 Middle East & Africa Addison’s Disease Drugs Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Addison’s Disease Drugs Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Bristol-Myers Squibb
11.1.1 Bristol-Myers Squibb Company Details
11.1.2 Bristol-Myers Squibb Business Overview
11.1.3 Bristol-Myers Squibb Addison’s Disease Drugs Introduction
11.1.4 Bristol-Myers Squibb Revenue in Addison’s Disease Drugs Business (2016-2021)
11.1.5 Bristol-Myers Squibb Recent Development
11.2 Merck
11.2.1 Merck Company Details
11.2.2 Merck Business Overview
11.2.3 Merck Addison’s Disease Drugs Introduction
11.2.4 Merck Revenue in Addison’s Disease Drugs Business (2016-2021)
11.2.5 Merck Recent Development
11.3 Novartis
11.3.1 Novartis Company Details
11.3.2 Novartis Business Overview
11.3.3 Novartis Addison’s Disease Drugs Introduction
11.3.4 Novartis Revenue in Addison’s Disease Drugs Business (2016-2021)
11.3.5 Novartis Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Details
11.4.2 Pfizer Business Overview
11.4.3 Pfizer Addison’s Disease Drugs Introduction
11.4.4 Pfizer Revenue in Addison’s Disease Drugs Business (2016-2021)
11.4.5 Pfizer Recent Development
11.5 Takeda Pharmaceutical
11.5.1 Takeda Pharmaceutical Company Details
11.5.2 Takeda Pharmaceutical Business Overview
11.5.3 Takeda Pharmaceutical Addison’s Disease Drugs Introduction
11.5.4 Takeda Pharmaceutical Revenue in Addison’s Disease Drugs Business (2016-2021)
11.5.5 Takeda Pharmaceutical Recent Development
11.6 Bio-Techne
11.6.1 Bio-Techne Company Details
11.6.2 Bio-Techne Business Overview
11.6.3 Bio-Techne Addison’s Disease Drugs Introduction
11.6.4 Bio-Techne Revenue in Addison’s Disease Drugs Business (2016-2021)
11.6.5 Bio-Techne Recent Development
11.7 GlaxoSmithKline
11.7.1 GlaxoSmithKline Company Details
11.7.2 GlaxoSmithKline Business Overview
11.7.3 GlaxoSmithKline Addison’s Disease Drugs Introduction
11.7.4 GlaxoSmithKline Revenue in Addison’s Disease Drugs Business (2016-2021)
11.7.5 GlaxoSmithKline Recent Development
11.8 Lupin Pharmaceuticals
11.8.1 Lupin Pharmaceuticals Company Details
11.8.2 Lupin Pharmaceuticals Business Overview
11.8.3 Lupin Pharmaceuticals Addison’s Disease Drugs Introduction
11.8.4 Lupin Pharmaceuticals Revenue in Addison’s Disease Drugs Business (2016-2021)
11.8.5 Lupin Pharmaceuticals Recent Development
11.9 Abbott
11.9.1 Abbott Company Details
11.9.2 Abbott Business Overview
11.9.3 Abbott Addison’s Disease Drugs Introduction
11.9.4 Abbott Revenue in Addison’s Disease Drugs Business (2016-2021)
11.9.5 Abbott Recent Development
11.10 Amgen
11.10.1 Amgen Company Details
11.10.2 Amgen Business Overview
11.10.3 Amgen Addison’s Disease Drugs Introduction
11.10.4 Amgen Revenue in Addison’s Disease Drugs Business (2016-2021)
11.10.5 Amgen Recent Development
11.11 Bayer
11.11.1 Bayer Company Details
11.11.2 Bayer Business Overview
11.11.3 Bayer Addison’s Disease Drugs Introduction
11.11.4 Bayer Revenue in Addison’s Disease Drugs Business (2016-2021)
11.11.5 Bayer Recent Development
11.12 Biogen
11.12.1 Biogen Company Details
11.12.2 Biogen Business Overview
11.12.3 Biogen Addison’s Disease Drugs Introduction
11.12.4 Biogen Revenue in Addison’s Disease Drugs Business (2016-2021)
11.12.5 Biogen Recent Development
11.13 Eli Lilly and Company
11.13.1 Eli Lilly and Company Company Details
11.13.2 Eli Lilly and Company Business Overview
11.13.3 Eli Lilly and Company Addison’s Disease Drugs Introduction
11.13.4 Eli Lilly and Company Revenue in Addison’s Disease Drugs Business (2016-2021)
11.13.5 Eli Lilly and Company Recent Development
11.14 Boehringer Ingelheim International
11.14.1 Boehringer Ingelheim International Company Details
11.14.2 Boehringer Ingelheim International Business Overview
11.14.3 Boehringer Ingelheim International Addison’s Disease Drugs Introduction
11.14.4 Boehringer Ingelheim International Revenue in Addison’s Disease Drugs Business (2016-2021)
11.14.5 Boehringer Ingelheim International Recent Development
11.15 Diurnal
11.15.1 Diurnal Company Details
11.15.2 Diurnal Business Overview
11.15.3 Diurnal Addison’s Disease Drugs Introduction
11.15.4 Diurnal Revenue in Addison’s Disease Drugs Business (2016-2021)
11.15.5 Diurnal Recent Development
11.16 Switzer Life Science
11.16.1 Switzer Life Science Company Details
11.16.2 Switzer Life Science Business Overview
11.16.3 Switzer Life Science Addison’s Disease Drugs Introduction
11.16.4 Switzer Life Science Revenue in Addison’s Disease Drugs Business (2016-2021)
11.16.5 Switzer Life Science Recent Development
11.17 Recipharm
11.17.1 Recipharm Company Details
11.17.2 Recipharm Business Overview
11.17.3 Recipharm Addison’s Disease Drugs Introduction
11.17.4 Recipharm Revenue in Addison’s Disease Drugs Business (2016-2021)
11.17.5 Recipharm Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Addison’s Disease Drugs Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Oral Drugs
Table 3. Key Players of Parenteral Drugs
Table 4. Global Addison’s Disease Drugs Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Addison’s Disease Drugs Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Addison’s Disease Drugs Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Addison’s Disease Drugs Market Share by Regions (2016-2021)
Table 8. Global Addison’s Disease Drugs Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Addison’s Disease Drugs Market Share by Regions (2022-2027)
Table 10. Addison’s Disease Drugs Market Trends
Table 11. Addison’s Disease Drugs Market Drivers
Table 12. Addison’s Disease Drugs Market Challenges
Table 13. Addison’s Disease Drugs Market Restraints
Table 14. Global Addison’s Disease Drugs Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Addison’s Disease Drugs Market Share by Players (2016-2021)
Table 16. Global Top Addison’s Disease Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Addison’s Disease Drugs as of 2020)
Table 17. Ranking of Global Top Addison’s Disease Drugs Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Addison’s Disease Drugs Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Addison’s Disease Drugs Product Solution and Service
Table 21. Date of Enter into Addison’s Disease Drugs Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Addison’s Disease Drugs Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Addison’s Disease Drugs Revenue Market Share by Type (2016-2021)
Table 25. Global Addison’s Disease Drugs Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Addison’s Disease Drugs Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Addison’s Disease Drugs Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global Addison’s Disease Drugs Revenue Market Share by Application (2016-2021)
Table 29. Global Addison’s Disease Drugs Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global Addison’s Disease Drugs Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America Addison’s Disease Drugs Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Addison’s Disease Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Addison’s Disease Drugs Market Size by Application (2016-2021) (US$ Million)
Table 34. North America Addison’s Disease Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America Addison’s Disease Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Addison’s Disease Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Addison’s Disease Drugs Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Addison’s Disease Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Addison’s Disease Drugs Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe Addison’s Disease Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe Addison’s Disease Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Addison’s Disease Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Addison’s Disease Drugs Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Addison’s Disease Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Addison’s Disease Drugs Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific Addison’s Disease Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Addison’s Disease Drugs Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Addison’s Disease Drugs Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Addison’s Disease Drugs Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Addison’s Disease Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Addison’s Disease Drugs Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America Addison’s Disease Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America Addison’s Disease Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Addison’s Disease Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Addison’s Disease Drugs Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Addison’s Disease Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Addison’s Disease Drugs Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa Addison’s Disease Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Addison’s Disease Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Addison’s Disease Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 61. Bristol-Myers Squibb Company Details
Table 62. Bristol-Myers Squibb Business Overview
Table 63. Bristol-Myers Squibb Addison’s Disease Drugs Product
Table 64. Bristol-Myers Squibb Revenue in Addison’s Disease Drugs Business (2016-2021) & (US$ Million)
Table 65. Bristol-Myers Squibb Recent Development
Table 66. Merck Company Details
Table 67. Merck Business Overview
Table 68. Merck Addison’s Disease Drugs Product
Table 69. Merck Revenue in Addison’s Disease Drugs Business (2016-2021) & (US$ Million)
Table 70. Merck Recent Development
Table 71. Novartis Company Details
Table 72. Novartis Business Overview
Table 73. Novartis Addison’s Disease Drugs Product
Table 74. Novartis Revenue in Addison’s Disease Drugs Business (2016-2021) & (US$ Million)
Table 75. Novartis Recent Development
Table 76. Pfizer Company Details
Table 77. Pfizer Business Overview
Table 78. Pfizer Addison’s Disease Drugs Product
Table 79. Pfizer Revenue in Addison’s Disease Drugs Business (2016-2021) & (US$ Million)
Table 80. Pfizer Recent Development
Table 81. Takeda Pharmaceutical Company Details
Table 82. Takeda Pharmaceutical Business Overview
Table 83. Takeda Pharmaceutical Addison’s Disease Drugs Product
Table 84. Takeda Pharmaceutical Revenue in Addison’s Disease Drugs Business (2016-2021) & (US$ Million)
Table 85. Takeda Pharmaceutical Recent Development
Table 86. Bio-Techne Company Details
Table 87. Bio-Techne Business Overview
Table 88. Bio-Techne Addison’s Disease Drugs Product
Table 89. Bio-Techne Revenue in Addison’s Disease Drugs Business (2016-2021) & (US$ Million)
Table 90. Bio-Techne Recent Development
Table 91. GlaxoSmithKline Company Details
Table 92. GlaxoSmithKline Business Overview
Table 93. GlaxoSmithKline Addison’s Disease Drugs Product
Table 94. GlaxoSmithKline Revenue in Addison’s Disease Drugs Business (2016-2021) & (US$ Million)
Table 95. GlaxoSmithKline Recent Development
Table 96. Lupin Pharmaceuticals Company Details
Table 97. Lupin Pharmaceuticals Business Overview
Table 98. Lupin Pharmaceuticals Revenue in Addison’s Disease Drugs Business (2016-2021) & (US$ Million)
Table 99. Lupin Pharmaceuticals Recent Development
Table 100. Abbott Company Details
Table 101. Abbott Business Overview
Table 102. Abbott Addison’s Disease Drugs Product
Table 103. Abbott Revenue in Addison’s Disease Drugs Business (2016-2021) & (US$ Million)
Table 104. Abbott Recent Development
Table 105. Amgen Company Details
Table 106. Amgen Business Overview
Table 107. Amgen Addison’s Disease Drugs Product
Table 108. Amgen Revenue in Addison’s Disease Drugs Business (2016-2021) & (US$ Million)
Table 109. Amgen Recent Development
Table 110. Bayer Company Details
Table 111. Bayer Business Overview
Table 112. Bayer Addison’s Disease Drugs Product
Table 113. Bayer Revenue in Addison’s Disease Drugs Business (2016-2021) & (US$ Million)
Table 114. Bayer Recent Development
Table 115. Biogen Company Details
Table 116. Biogen Business Overview
Table 117. Biogen Addison’s Disease Drugs Product
Table 118. Biogen Revenue in Addison’s Disease Drugs Business (2016-2021) & (US$ Million)
Table 119. Biogen Recent Development
Table 120. Eli Lilly and Company Company Details
Table 121. Eli Lilly and Company Business Overview
Table 122. Eli Lilly and Company Addison’s Disease Drugs Product
Table 123. Eli Lilly and Company Revenue in Addison’s Disease Drugs Business (2016-2021) & (US$ Million)
Table 124. Eli Lilly and Company Recent Development
Table 125. Boehringer Ingelheim International Company Details
Table 126. Boehringer Ingelheim International Business Overview
Table 127. Boehringer Ingelheim International Addison’s Disease Drugs Product
Table 128. Boehringer Ingelheim International Revenue in Addison’s Disease Drugs Business (2016-2021) & (US$ Million)
Table 129. Boehringer Ingelheim International Recent Development
Table 130. Diurnal Company Details
Table 131. Diurnal Business Overview
Table 132. Diurnal Addison’s Disease Drugs Product
Table 133. Diurnal Revenue in Addison’s Disease Drugs Business (2016-2021) & (US$ Million)
Table 134. Diurnal Recent Development
Table 135. Switzer Life Science Company Details
Table 136. Switzer Life Science Business Overview
Table 137. Switzer Life Science Addison’s Disease Drugs Product
Table 138. Switzer Life Science Revenue in Addison’s Disease Drugs Business (2016-2021) & (US$ Million)
Table 139. Switzer Life Science Recent Development
Table 140. Recipharm Company Details
Table 141. Recipharm Business Overview
Table 142. Recipharm Addison’s Disease Drugs Product
Table 143. Recipharm Revenue in Addison’s Disease Drugs Business (2016-2021) & (US$ Million)
Table 144. Recipharm Recent Development
Table 145. Research Programs/Design for This Report
Table 146. Key Data Information from Secondary Sources
Table 147. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Addison’s Disease Drugs Market Share by Type: 2020 VS 2027
Figure 2. Oral Drugs Features
Figure 3. Parenteral Drugs Features
Figure 4. Global Addison’s Disease Drugs Market Share by Application: 2020 VS 2027
Figure 5. Hospitals Case Studies
Figure 6. Specialty Clinics Case Studies
Figure 7. Addison’s Disease Drugs Report Years Considered
Figure 8. Global Addison’s Disease Drugs Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 9. Global Addison’s Disease Drugs Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 10. Global Addison’s Disease Drugs Market Share by Regions: 2020 VS 2027
Figure 11. Global Addison’s Disease Drugs Market Share by Regions (2022-2027)
Figure 12. Global Addison’s Disease Drugs Market Share by Players in 2020
Figure 13. Global Top Addison’s Disease Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Addison’s Disease Drugs as of 2020
Figure 14. The Top 10 and 5 Players Market Share by Addison’s Disease Drugs Revenue in 2020
Figure 15. Global Addison’s Disease Drugs Revenue Market Share by Type (2016-2021)
Figure 16. Global Addison’s Disease Drugs Revenue Market Share by Type (2022-2027)
Figure 17. North America Addison’s Disease Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 18. North America Addison’s Disease Drugs Market Share by Type (2016-2027)
Figure 19. North America Addison’s Disease Drugs Market Share by Application (2016-2027)
Figure 20. North America Addison’s Disease Drugs Market Share by Country (2016-2027)
Figure 21. United States Addison’s Disease Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. Canada Addison’s Disease Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. Europe Addison’s Disease Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Europe Addison’s Disease Drugs Market Share by Type (2016-2027)
Figure 25. Europe Addison’s Disease Drugs Market Share by Application (2016-2027)
Figure 26. Europe Addison’s Disease Drugs Market Share by Country (2016-2027)
Figure 27. Germany Addison’s Disease Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. France Addison’s Disease Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. U.K. Addison’s Disease Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. Italy Addison’s Disease Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Russia Addison’s Disease Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Nordic Addison’s Disease Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Asia-Pacific Addison’s Disease Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Asia-Pacific Addison’s Disease Drugs Market Share by Type (2016-2027)
Figure 35. Asia-Pacific Addison’s Disease Drugs Market Share by Application (2016-2027)
Figure 36. Asia-Pacific Addison’s Disease Drugs Market Share by Region (2016-2027)
Figure 37. China Addison’s Disease Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Japan Addison’s Disease Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. South Korea Addison’s Disease Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Southeast Asia Addison’s Disease Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. India Addison’s Disease Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Australia Addison’s Disease Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Latin America Addison’s Disease Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Latin America Addison’s Disease Drugs Market Share by Type (2016-2027)
Figure 45. Latin America Addison’s Disease Drugs Market Share by Application (2016-2027)
Figure 46. Latin America Addison’s Disease Drugs Market Share by Country (2016-2027)
Figure 47. Mexico Addison’s Disease Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Brazil Addison’s Disease Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Middle East & Africa Addison’s Disease Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Middle East & Africa Addison’s Disease Drugs Market Share by Type (2016-2027)
Figure 51. Middle East & Africa Addison’s Disease Drugs Market Share by Application (2016-2027)
Figure 52. Middle East & Africa Addison’s Disease Drugs Market Share by Country (2016-2027)
Figure 53. Turkey Addison’s Disease Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Saudi Arabia Addison’s Disease Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. UAE Addison’s Disease Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Bristol-Myers Squibb Revenue Growth Rate in Addison’s Disease Drugs Business (2016-2021)
Figure 57. Merck Revenue Growth Rate in Addison’s Disease Drugs Business (2016-2021)
Figure 58. Novartis Revenue Growth Rate in Addison’s Disease Drugs Business (2016-2021)
Figure 59. Pfizer Revenue Growth Rate in Addison’s Disease Drugs Business (2016-2021)
Figure 60. Takeda Pharmaceutical Revenue Growth Rate in Addison’s Disease Drugs Business (2016-2021)
Figure 61. Bio-Techne Revenue Growth Rate in Addison’s Disease Drugs Business (2016-2021)
Figure 62. GlaxoSmithKline Revenue Growth Rate in Addison’s Disease Drugs Business (2016-2021)
Figure 63. Lupin Pharmaceuticals Revenue Growth Rate in Addison’s Disease Drugs Business (2016-2021)
Figure 64. Abbott Revenue Growth Rate in Addison’s Disease Drugs Business (2016-2021)
Figure 65. Amgen Revenue Growth Rate in Addison’s Disease Drugs Business (2016-2021)
Figure 66. Bayer Revenue Growth Rate in Addison’s Disease Drugs Business (2016-2021)
Figure 67. Biogen Revenue Growth Rate in Addison’s Disease Drugs Business (2016-2021)
Figure 68. Eli Lilly and Company Revenue Growth Rate in Addison’s Disease Drugs Business (2016-2021)
Figure 69. Boehringer Ingelheim International Revenue Growth Rate in Addison’s Disease Drugs Business (2016-2021)
Figure 70. Diurnal Revenue Growth Rate in Addison’s Disease Drugs Business (2016-2021)
Figure 71. Switzer Life Science Revenue Growth Rate in Addison’s Disease Drugs Business (2016-2021)
Figure 72. Recipharm Revenue Growth Rate in Addison’s Disease Drugs Business (2016-2021)
Figure 73. Bottom-up and Top-down Approaches for This Report
Figure 74. Data Triangulation
Figure 75. Key Executives Interviewed
世界のアジソン病検査市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Addison Disease Testing Market The global Addison Disease Testing market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, the re…- 世界のアジソン病治療市場規模・現状・予測（2021年-2027年） Addison’s Disease is to point to because adrenal cortex hormone secretion is insufficient a kind of systemic disease that causes.Those caused by adrenal gland diseases themselves are called primary adrenocortical hypoxia, and those caused by hypothalamus and/or pituitary diseases are called secondar…
- 世界のアジソン病治療市場規模・現状・予測（2021年-2027年） Addison’s Disease is to point to because adrenal cortex hormone secretion is insufficient a kind of systemic disease that causes.Those caused by adrenal gland diseases themselves are called primary adrenocortical hypoxia, and those caused by hypothalamus and/or pituitary diseases are called secondar…
- 世界のアジソン病検査市場 2021：企業別、地域別、種類・用途別 The Addison Disease Testing market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulat…
- 世界のクラッベ病治療薬市場規模・現状・予測（2021年-2027年） Krabbe disease is an uncommon and typically deadly concern of the nervous system. It is an acquired hereditary sickness, which implies that it is passed down in families. Individuals with Krabbe disease are not able to make a sufficient substance called galactosylceramidase, which is expected to mak…